- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | MindMed begins phase 3 study of MM120 for anxiety disorder | ||
| Di | German cancer centre treats first patient with Elekta Evo | ||
| Mo | CSL receives positive opinion for garadacimab in hereditary angioedema | ||
| Mo | Beckley Psytech announces positive results for ELE-101 in depression trial | ||
| 12.12. | Bayer begins SOS1 inhibitor study treating advanced KRAS-mutated tumours | ||
| 12.12. | Leriglitazone meets primary endpoint in pivotal cALD trial | ||
| 11.12. | iOnctura achieves new clinical milestones in uveal melanoma therapy | ||
| 11.12. | Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy | ||
| 10.12. | Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis | ||
| 10.12. | CatalYm shows potential of visugromab for treating cachexia | ||
| 09.12. | Imfinzi receives NICE recommendation for lung cancer treatment | ||
| 09.12. | Poolbeg Pharma presents positive results for POLB 001 | ||
| 05.12. | Teva's Ajovy shows positive results in preventing pediatric migraines | ||
| 05.12. | NICE endorses Neuraxpharm's ublituximab for treating MS | ||
| 04.12. | Antag Therapeutics secures €80 million in weight loss therapy financing | ||
| 04.12. | Everest therapy shows promise in nephropathy trial | ||
| 03.12. | KIMMTRAK recommended for funding by NICE for uveal melanoma patients | ||
| 03.12. | Orbit Discovery and Evergreen Theragnostics expand research collaboration | ||
| 02.12. | OGT launches enhanced genetic profiling panel for CLL | ||
| 02.12. | Pharma giants vie for oral GLP-1R approval | ||
| 28.11. | New injection offers hope for asthma and COPD attacks | ||
| 28.11. | Scientists join forces to speed up vaccine development with new technology | ||
| 21.11. | Cytomos raises $5m to scale up cell analysis technology production | ||
| 20.11. | Ardena's expanded nanomedicine facility granted full GMP approval | ||
| 19.11. | New PAGB research highlights importance of self-care for easy-to-treat conditions |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
